Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL28090943 | 0.96 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL197824 | 0.96 | TSHR (0.33) | TSHRALDH1A1 | |
| Lithium Ion SCHEMBL2504315 | 0.92 | TSHR (0.31) | TSHRALDH1A1 | |
| SCHEMBL5327333 | 0.92 | TSHR (0.31) | TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4552701 | 0.92 | TSHR (0.31) | TSHRALDH1A1 | |
| SCHEMBL5327324 | 0.92 | TSHR (0.31) | TSHRALDH1A1 | |
| Fluoride Ion SCHEMBL1260645 | 0.92 | TSHR (0.31) | TSHRALDH1A1 | |
| Fluoride Ion SCHEMBL33106 | 0.92 | TSHR (0.31) | TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL20896 | 0.92 | TSHR (0.31) | TSHRALDH1A1 | |
| SCHEMBL2504316 | 0.92 | TSHR (0.31) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179925-B2 | Method for reducing organic compounds in microreactor by means of hydrides and/or the derivatives thereof | MERCK PATENT GMBH (DE) | 2007-02-20 | — | — | US | claimed |
| EP-0033553-B1 | NICKEL COMPLEXES IN DIOL SOLVENTS AND THEIR USE AS PART OF A CATALYST IN THE OLIGOMERIZATION OF ETHYLENE | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1984-06-06 | — | — | EP | claimed |
| EP-0033553-A2 | Nickel complexes in diol solvents and their use as part of a catalyst in the oligomerization of ethylene | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1981-08-12 | — | — | EP | claimed |
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-05-12 | — | — | US | disclosed |
| US-11309098-B2 | Mineralogical method and apparatus for removal of aqueous cesium ion | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2022-04-19 | — | — | US | disclosed |
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-12-03 | — | — | US | disclosed |
| US-20200258646-A1 | MINERALOGICAL METHOD AND APPARATUS FOR REMOVAL OF AQUEOUS CESIUM ION | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2020-08-13 | — | — | US | disclosed |
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| EP-2917214-B1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-08-28 | — | — | EP | disclosed |
| US-20190241546-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-08-08 | — | — | US | disclosed |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-10-11 | — | — | US | disclosed |
| WO-2007045420-A2 | 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFUTRAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007009898-A1 | 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-25 | — | — | WO | disclosed |
| US-7112682-B2 | Process for the preparation of N-amino substituted heterocyclic compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1678135-A1 | PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS | Aventis Pharmaceuticals, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050101654-A1 | Process for the preparation of N-amino substituted heterocyclic compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005035496-A1 | PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-6380238-B1 | FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-30 | — | — | US | disclosed |
| EP-1109784-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012475-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | TSHR 2999/4885ALDH1A1 1683/4885 |
| US-20190241546-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | TSHR 2999/4885ALDH1A1 1683/4885 |
| US-20050101654-A1 | Process for the preparation of N-amino substituted heterocyclic compounds | AADAT, KMO, KYNU | TSHR 3627/4885ALDH1A1 1230/4885 |
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | TSHR 2999/4885ALDH1A1 1683/4885 |
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | TSHR 3355/4885ALDH1A1 1999/4885 |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | TSHR 3355/4885ALDH1A1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.